Literature DB >> 24758914

The screening of the 3'UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease.

Lucía F Cardo1, Eliecer Coto2, René Ribacoba3, Ignacio F Mata4, Germán Moris3, Manuel Menéndez3, Victoria Alvarez1.   

Abstract

Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic determinants of familial and sporadic Parkinson's disease (PD). Most of the mutational screenings analyzed the exon-coding sequence. Our aim was to determine whether LRRK2 3' untranslated region (UTR) variants were associated with the risk of developing PD in a large cohort of patients (n=743) and controls (n=523) from Spain. We identified a total of 12 3'UTR variants (two new). Single-nucleotide polymorphism (SNP) rs66737902 C allele was overrepresented in patients (P=0.005; odds ratio=1.47). This SNP was in linkage disequilibrium with the p.R1441G mutation, but the association remained significant among mutation-negative cases. We found a significant lower level of the LRRK2 transcript in the Substantia nigra (SN) of PD postmortem donors (n=9) who were rs66737902 C carriers (P=0.01). This SNP was predicted to affect a binding site for miR-138-2-3p. We showed that this microRNA was expressed in all the SN samples. In conclusion, we found a significant association between SNP rs66737902 and the risk of developing PD. This effect on PD risk could be explained by differences in LRRK2 transcript levels between the two alleles.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24758914     DOI: 10.1038/jhg.2014.26

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  17 in total

1.  Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.

Authors:  María C González-Fernández; Elena Lezcano; Owen A Ross; Juan C Gómez-Esteban; Fernando Gómez-Busto; Fernando Velasco; Maite Alvarez-Alvarez; María B Rodríguez-Martínez; Roberto Ciordia; Juan J Zarranz; Matthew J Farrer; Ignacio F Mata; Marian M de Pancorbo
Journal:  Parkinsonism Relat Disord       Date:  2007-05-30       Impact factor: 4.891

2.  Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.

Authors:  Stephan Gehrke; Yuzuru Imai; Nicholas Sokol; Bingwei Lu
Journal:  Nature       Date:  2010-07-29       Impact factor: 49.962

3.  Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe.

Authors:  Justin P Rubio; Simon Topp; Liling Warren; Pamela L St Jean; Daniel Wegmann; Darren Kessner; John Novembre; Judong Shen; Dana Fraser; Jennifer Aponte; Keith Nangle; Lon R Cardon; Margaret G Ehm; Stephanie L Chissoe; John C Whittaker; Matthew R Nelson; Vincent E Mooser
Journal:  Hum Mutat       Date:  2012-04-04       Impact factor: 4.878

4.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

5.  Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.

Authors:  Shinji Higashi; Saskia Biskup; Andrew B West; Daniel Trinkaus; Valina L Dawson; Richard L M Faull; Henry J Waldvogel; Heii Arai; Ted M Dawson; Darren J Moore; Piers C Emson
Journal:  Brain Res       Date:  2007-04-19       Impact factor: 3.252

6.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis.

Authors:  Patrick A Lewis; Elisa Greggio; Alexandra Beilina; Shushant Jain; Acacia Baker; Mark R Cookson
Journal:  Biochem Biophys Res Commun       Date:  2007-04-10       Impact factor: 3.575

7.  Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort.

Authors:  Yah-Huei Wu-Chou; Ying-Ting Chen; Tu-Hsueh Yeh; Hsiu-Chen Chang; Yi-Hsin Weng; Szu-Chia Lai; Chia-Ling Huang; Rou-Shayn Chen; Ying-Zu Huang; Chiung-Chu Chen; June Hung; Wen-Li Chuang; Wey-Yil Lin; Chien-Hsiun Chen; Chin-Song Lu
Journal:  Parkinsonism Relat Disord       Date:  2012-11-20       Impact factor: 4.891

8.  Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease.

Authors:  Naomi Seki; Yuji Takahashi; Hiroyuki Tomiyama; Ekaterina Rogaeva; Shigeo Murayama; Yoshikuni Mizuno; Nobutaka Hattori; Connie Marras; Anthony E Lang; Peter St George-Hyslop; Jun Goto; Shoji Tsuji
Journal:  J Hum Genet       Date:  2011-07-28       Impact factor: 3.172

9.  Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms.

Authors:  Lucía F Cardo; Eliecer Coto; Lorena de Mena; René Ribacoba; Ignacio F Mata; Manuel Menéndez; Germán Moris; Victoria Alvarez
Journal:  Neurosci Lett       Date:  2014-01-10       Impact factor: 3.046

10.  Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.

Authors:  Michael J Devine; Alice Kaganovich; Mina Ryten; Adamantios Mamais; Daniah Trabzuni; Claudia Manzoni; Philip McGoldrick; Diane Chan; Allissa Dillman; Julia Zerle; Susannah Horan; Jan-Willem Taanman; John Hardy; Jose-Felix Marti-Masso; Daniel Healy; Daniel Healey; Anthony H Schapira; Benjamin Wolozin; Rina Bandopadhyay; Mark R Cookson; Marcel P van der Brug; Patrick A Lewis
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

View more
  7 in total

Review 1.  MicroRNAs in Parkinson's disease.

Authors:  Abhishek Singh; Dwaipayan Sen
Journal:  Exp Brain Res       Date:  2017-05-19       Impact factor: 1.972

2.  MiRNA profile in the substantia nigra of Parkinson's disease and healthy subjects.

Authors:  Lucía F Cardo; Eliecer Coto; René Ribacoba; Manuel Menéndez; Germán Moris; Esther Suárez; Victoria Alvarez
Journal:  J Mol Neurosci       Date:  2014-10-05       Impact factor: 3.444

Review 3.  Hypo- and Hyper-Assembly Diseases of RNA-Protein Complexes.

Authors:  Siddharth Shukla; Roy Parker
Journal:  Trends Mol Med       Date:  2016-06-03       Impact factor: 11.951

Review 4.  microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.

Authors:  Loredana Leggio; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Salvo Caniglia; Nunzio Testa; Bianca Marchetti; Nunzio Iraci
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

Review 5.  Mitochondrial MicroRNAs in Aging and Neurodegenerative Diseases.

Authors:  Albin John; Aaron Kubosumi; P Hemachandra Reddy
Journal:  Cells       Date:  2020-05-28       Impact factor: 6.600

Review 6.  The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.

Authors:  Simoneide S Titze-de-Almeida; Cristina Soto-Sánchez; Eduardo Fernandez; James B Koprich; Jonathan M Brotchie; Ricardo Titze-de-Almeida
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

7.  Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.

Authors:  Selma Yılmazer; Esin Candaş; Gençer Genç; Merve Alaylıoğlu; Büşra Şengül; Ayşegül Gündüz; Hülya Apaydın; Güneş Kızıltan; Sibel Ertan; Erdinç Dursun; Duygu Gezen-Ak
Journal:  Neuromolecular Med       Date:  2020-10-04       Impact factor: 3.843

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.